“Assessment of Patients Affected by Rheumatoid Arthritis Eligible for Biotechnological Agents and Evaluation of Their Healthcare Resource Utilization and Related Costs”. Reumatismo, vol. 73, no. 1, Apr. 2021, pp. 5-14, https://doi.org/10.4081/reumatismo.2021.1329.